TG Therapeutics, Inc.'s Q4 2026/H1 2027 will be rich in catalysts. From the presentation of prelimin

Deutsche Bank AG purchased a new stake in TG Therapeutics, Inc. (NASDAQ: TGTX) in the undefined quar

Shares of TG Therapeutics rose this week after buyout rumors surfaced. TG is a prime takeover target

Dow Jones index gained around 350 points on Friday. MARA Holdings Inc (NASDAQ: MARA) rose sharply, w

Bank of America Corp DE lifted its position in TG Therapeutics, Inc. (NASDAQ: TGTX) by 71.7% in the

Assenagon Asset Management S.A. decreased its holdings in shares of TG Therapeutics, Inc. (NASDAQ: T

TG Therapeutics, Inc. (NASDAQ: TGTX - Get Free Report) has earned an average rating of "Hold" from t

JP Morgan analyst Brian Cheng maintains TG Therapeutics (NASDAQ:TGTX) with a Overweight and raise

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its nove

Empowered Funds LLC lifted its position in TG Therapeutics, Inc. (NASDAQ: TGTX) by 49.9% in the unde

TG Therapeutics, Inc. remains a Buy as BRIUMVI's momentum supports a durable, growing multiple scler

TG Therapeutics misses Q2 earnings estimates, but surging Briumvi demand lifts revenues y/y and prom

TG Therapeutics, Inc. (TGTX) Q2 2026 Earnings Call Transcript

The headline numbers for TG Therapeutics (TGTX) give insight into how the company performed in the q

TG Therapeutics NASDAQ: TGTX reported second-quarter 2026 revenue of $240 million and raised its ful

TG Therapeutics (TGTX) came out with quarterly earnings of $0.05 per share, missing the Zacks Consen

TG Therapeutics (NASDAQ:TGTX) raises FY2026 sales outlook from $925.000 million to $950.000 million

TG Therapeutics (NASDAQ:TGTX) reported quarterly earnings of $0.05 per share which missed the analys

Second quarter 2026 total global revenue of approximately $240 million, including BRIUMVI U.S. net p

NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced th

B. Riley Securities analyst William Woods maintains TG Therapeutics (NASDAQ:TGTX) with a Buy and

TG Therapeutics (TGTX) possesses the right combination of the two key ingredients for a likely earni

NEW YORK, July 21, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is inves

NEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is i

HC Wainwright & Co. analyst Emily Bodnar maintains TG Therapeutics (NASDAQ:TGTX) with a Buy a

B of A Securities analyst Alec Stranahan maintains TG Therapeutics (NASDAQ:TGTX) with a Underperf

HC Wainwright & Co. analyst Emily Bodnar reiterates TG Therapeutics (NASDAQ:TGTX) with a Buy

TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the initiation of a Phase 2 clinical trial eval

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

TG Therapeutics shares are trading higher on Thursday as traders keep leaning into recent upbeat cli

3 health care stocks flashing warning: CAH RSI 77.7, TGTX RSI 79.8, AMRX RSI 76.9; all overbought, b

TG Therapeutics shares are trading higher on Wednesday as positive topline Phase 1 data fuels fresh

US stocks down, Dow Jones fell 150 pts on Wed. Caseys General Stores Inc (CASY) shares up 14.4% afte

TGTX stock rises on positive Phase 1 data for subcutaneous BRIUMVI in myasthenia gravis. See what&#3

82% of subjects achieved an MCID in their MG-ADL with a mean >4 point improvement in MG-ADL obser

82% of subjects achieved an MCID in their MG-ADL with a mean >4 point improvement in MG-ADL obser

Shares of TG Therapeutics Inc (NASDAQ: TGTX) are climbing Wednesday after early-stage clinical trial

Dow falls 296 points. Navitas Semi rises on partnership with Nvidia. Other gainers: ABVX, MMED, KELY

Pharmacokinetic and pharmacodynamic data support quarterly subcutaneous BRIUMVI dosing regimen curre

TG Therapeutics, Inc. (NASDAQ:TGTX), today announced the publication of data from a post-hoc pooled

HC Wainwright & Co. analyst Emily Bodnar reiterates TG Therapeutics (NASDAQ:TGTX) with a Buy

Phase 3 trial met its primary endpoint, demonstrating bioequivalent drug exposure between the curren

TG Therapeutics, Inc. (NASDAQ:TGTX), today announced the upcoming schedule of presentations highligh

HC Wainwright & Co. analyst Emily Bodnar maintains TG Therapeutics (NASDAQ:TGTX) with a Buy a

TG Therapeutics (NASDAQ:TGTX) reported quarterly earnings of $0.18 per share which missed the analys

TG Therapeutics (NASDAQ:TGTX) raises FY2026 sales outlook from $875.000 million-$900.000 million to

BRIUMVI is currently approved in the United States and several ex-US territories as a one-hour intra

https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/october-december-2025-new-safety-

TG Therapeutics, Inc. ("TG" or "the Company"), (NASDAQ:TGTX), today announced that i